Literature DB >> 3903517

Sequence of human tissue inhibitor of metalloproteinases and its identity to erythroid-potentiating activity.

A J Docherty, A Lyons, B J Smith, E M Wright, P E Stephens, T J Harris, G Murphy, J J Reynolds.   

Abstract

Collagen fibres form the stable architecture of connective tissues and their breakdown is a key irreversible step in many pathological conditions. The destruction of collagen is usually initiated by proteinases, the best known of which is the metalloproteinase collagenase (EC 3.4.24). Collagenase and related metalloproteinases are regulated at the level of their synthesis and secretion, through the action of specific stimuli such as hormones and cytokines, and also at the level of their extracellular activity through the action of a specific inhibitor, TIMP (tissue inhibitor of metalloproteinases), which irreversibly forms inactive complexes with metalloproteinases. Although the mechanisms governing the production of TIMP are unknown, immunologically identical forms of this glycoprotein have been detected in a wide variety of human body fluids and cell and tissue culture media. We therefore suggested that under physiological conditions this ubiquitous inhibitor predominates over active metalloproteinases and that tissue destruction may arise when any perturbation of this controlling excess arises. However, further progress towards testing this theory has been hindered by a lack of knowledge about the structure of TIMP and insufficient material for studying it in model systems. Here we describe the structure of TIMP predicted from its complementary DNA, its synthesis in Escherichia coli and transfected animal cells, and the finding that it is identical to a protein recently reported to have erythroid-potentiating activity (EPA).

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3903517     DOI: 10.1038/318066a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  131 in total

Review 1.  A case of tumor betrayal: biphasic effects of TIMP-1 on Burkitt's lymphoma.

Authors:  L Yan; M A Moses
Journal:  Am J Pathol       Date:  2001-04       Impact factor: 4.307

Review 2.  The plasmin cascade and matrix metalloproteinases in non-small cell lung cancer.

Authors:  G Cox; W P Steward; K J O'Byrne
Journal:  Thorax       Date:  1999-02       Impact factor: 9.139

3.  Tissue inhibitor of metalloproteinase-1 and -2 RNA expression in rat and human liver fibrosis.

Authors:  H Herbst; T Wege; S Milani; G Pellegrini; H D Orzechowski; W O Bechstein; P Neuhaus; A M Gressner; D Schuppan
Journal:  Am J Pathol       Date:  1997-05       Impact factor: 4.307

Review 4.  MMPs and TIMPs--an historical perspective.

Authors:  J Frederick Woessner
Journal:  Mol Biotechnol       Date:  2002-09       Impact factor: 2.695

5.  Role of the 21-kDa protein TIMP-3 in oncogenic transformation of cultured chicken embryo fibroblasts.

Authors:  T T Yang; S P Hawkes
Journal:  Proc Natl Acad Sci U S A       Date:  1992-11-15       Impact factor: 11.205

6.  The architecture of cancer.

Authors:  J Waxman; H Wasan
Journal:  BMJ       Date:  1992-11-28

7.  Human 72-kilodalton type IV collagenase forms a complex with a tissue inhibitor of metalloproteases designated TIMP-2.

Authors:  G I Goldberg; B L Marmer; G A Grant; A Z Eisen; S Wilhelm; C S He
Journal:  Proc Natl Acad Sci U S A       Date:  1989-11       Impact factor: 11.205

8.  Phosphatidylinositol 3-kinase/Akt induced by erythropoietin renders the erythroid differentiation factor GATA-1 competent for TIMP-1 gene transactivation.

Authors:  Zahra Kadri; Leila Maouche-Chretien; Heather M Rooke; Stuart H Orkin; Paul-Henri Romeo; Patrick Mayeux; Philippe Leboulch; Stany Chretien
Journal:  Mol Cell Biol       Date:  2005-09       Impact factor: 4.272

9.  Crystal structure of the complex formed by the membrane type 1-matrix metalloproteinase with the tissue inhibitor of metalloproteinases-2, the soluble progelatinase A receptor.

Authors:  C Fernandez-Catalan; W Bode; R Huber; D Turk; J J Calvete; A Lichte; H Tschesche; K Maskos
Journal:  EMBO J       Date:  1998-09-01       Impact factor: 11.598

10.  Gene transfer for the treatment of neovascular ocular disease (an American Ophthalmological Society thesis).

Authors:  John Timothy Stout
Journal:  Trans Am Ophthalmol Soc       Date:  2006
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.